triple incretin agonist · GIP / GLP-1 / glucagon
retatrutide, in research terms
Also known as LY3437943.
Retatrutide (development code LY3437943) is the most-studied triple incretin agonist. It is the compound researchers reach for when the question involves engaging the glucagon receptor alongside the two incretin receptors — a step beyond the dual-agonist generation.
what it is
Retatrutide is a single synthetic peptide that acts as an agonist at three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor. That three-way profile is what defines it and what separates it from earlier compounds in the metabolic range.
the mechanism, at a research level
The two incretin arms — GIP and GLP-1 — are the receptors associated in the literature with glucose-dependent insulin signalling and appetite regulation. The third arm, the glucagon receptor, is studied in the context of energy expenditure and hepatic metabolism. Engaging all three is the hypothesis retatrutide exists to test: whether adding controlled glucagon-receptor agonism to dual incretin agonism changes the metabolic profile.
"Triple" is not shorthand for "stronger" — it describes a different receptor footprint, and the research value is in that difference, not in a ranking.
how it differs from tirzepatide
The natural reference point is tirzepatide, a dual GIP/GLP-1 agonist. Retatrutide adds the glucagon arm; tirzepatide does not have it. Evidence maturity also differs — the dual-agonist class has a longer research record. For a criteria-by-criteria view, see retatrutide vs tirzepatide.
verifying identity and purity
Retatrutide is high-potency, so identity and concentration data matter more here than almost anywhere in the catalogue. Every research pen ships with an independent, batch-specific certificate of analysis reporting LC-MS identity and HPLC purity, so the compound is checked before any research use rather than taken on trust. See how to read a COA.
research use only
This compound is supplied strictly for in-vitro and laboratory research use only. It is not a medicine, is not for human or veterinary consumption, and nothing on this page is dosing, medical or treatment guidance. Any effect described is stated in the context of published research, not a claim about use.
where to find Retatrutide
Retatrutide is supplied in the following research pens — pre-filled, batch-numbered and independently assayed. Save one to your list and we'll email you the moment it's available in your country.
